Chemical Industry and Engineering Progress ›› 2021, Vol. 40 ›› Issue (6): 3401-3410.DOI: 10.16085/j.issn.1000-6613.2020-1448

• Biochemical and pharmaceutical engineering • Previous Articles     Next Articles

Research progress of recombinant human growth hormone delivery systems

LI Yao1(), JU Xiaojie1,2(), WANG Wei1,2, LIU Zhuang1,2, XIE Rui1,2, CHU Liangyin1,2   

  1. 1.School of Chemical Engineering, Sichuan University, Chengdu 610065, Sichuan, China
    2.State Key Laboratory of Polymer Materials Engineering, Sichuan University, Chengdu 610065, Sichuan, China
  • Received:2020-07-27 Revised:2020-09-01 Online:2021-06-22 Published:2021-06-06
  • Contact: JU Xiaojie

重组人生长激素给药系统的研究进展

李瑶1(), 巨晓洁1,2(), 汪伟1,2, 刘壮1,2, 谢锐1,2, 褚良银1,2   

  1. 1.四川大学化学工程学院,四川 成都 610065
    2.四川大学高分子材料工程国家重点实验室,四川 成都 610065
  • 通讯作者: 巨晓洁
  • 作者简介:李瑶(1996—),女,硕士研究生。E-mail:1047176112@qq.com
  • 基金资助:
    国家自然科学基金重大项目(21991101)

Abstract:

Recombinant human growth hormone (rhGH) is the first choice to treat various growth hormone deficiencies and complications. But the rhGH requires long-term and frequent injection clinically. Long-acting rhGH preparations and non-injection administration routes can significantly increase patient compliance. In this paper, the types, effectiveness and development status of long-acting rhGH preparations and non-injection administration routes were reviewed. The research status and latest progress of rhGH long-acting methods (such as chemical modification, construction of fusion proteins, construction of sustained-release microspheres) and non-injection routes of rhGH (such as transdermal, pulmonary, nasal administrations) were introduced. The potential application problems of these rhGH delivery systems were analyzed, so that readers can have a more comprehensive and clear understanding of the research status in this field. The future development direction of this field was also proposed, that the rational combination of long-acting and non-injection administration would be an important research direction to achieve high-efficiency delivery of rhGH in the future. This paper provides a reference for the further development of a new safe and effective rhGH drug delivery system.

Key words: recombinant human growth hormone(rhGH), long-acting preparation, non-injection administration route

摘要:

重组人生长激素(rhGH)是治疗各种生长激素缺乏症及并发症的首选药物,但临床上需长期频繁注射给药,实现rhGH长效化和改变给药途径可显著提高患者依从性,具有重要的研究价值。本文针对近年来rhGH长效化制剂和非注射给药途径的类型、有效性及开发现状进行了综述,主要介绍了利用化学修饰、构建融合蛋白、构建缓释微球等rhGH长效化方法以及经皮给药、肺部给药、鼻腔黏膜给药等rhGH非注射给药途径的研究现状和最新进展,分析了各类rhGH给药系统在应用方面的潜在问题,以期使读者对该领域的研究状况有更全面、更清楚的了解;并指出了该研究领域未来的发展方向,提出了将rhGH长效化与非注射给药途径合理结合应是将来实现rhGH高效递送的重要研究方向,以期为进一步开发安全有效的rhGH新型给药系统提供参考。

关键词: 重组人生长激素, 长效化制剂, 非注射给药途径

CLC Number: 

京ICP备12046843号-2;京公网安备 11010102001994号
Copyright © Chemical Industry and Engineering Progress, All Rights Reserved.
E-mail: hgjz@cip.com.cn
Powered by Beijing Magtech Co. Ltd